Biogen has finalised a $900 million payment to settle a whistleblower lawsuit claiming that it paid kickbacks to US doctors to prescribe its multiple sclerosis drugs. According to a Department of ...

Apitope hopes its MS hopeful ATX-MS-1467 will become a blockbuster, even though Merck KGaA walked away from clinical development at the end of last year. Keith Martin, CEO of Apitope said he hopes the ...

DMTs slow the progression of multiple sclerosis and reduce relapse severity. Starting DMTs soon after diagnosis can help ...

Most drugs withdrawn from the market because of serious toxicities never make it back. But Biogen Idec succeeded in getting its multiple sclerosis (MS) drug Tysabri reintroduced in less than 16 months ...

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, ...

Medicare covers various aspects of multiple sclerosis (MS) treatment, including medications, therapy, hospital stays, and medical equipment, but the specific coverage depends on the Medicare plan.